Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japanese prospective registry of first-line A-AVD for newly diagnosed Hodgkin lymphoma
jRCTs071200092Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brentuximab vedotin, doxorubicin, vinblastine and dacarbazine in Hodgkin lymphoma (HL) and classical Hodgkin lymphoma (cHL), sponsored by Takeda. Primary endpoint: Complete response rate. Started Mar 2021; status: active, not recruiting.
02
Drugs
brentuximab vedotindoxorubicinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCTs071200092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200092.